ArticleGut2011
Association of TNFSF15 polymorphism with irritable bowel syndrome.
Article in Gut, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 61 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
61 citing papers in PubMed, 125 citations in OpenAlex.
- Trial
- Duloxetine as a gut-brain axis modulator in irritable bowel syndrome: neuroimmune, microbiota, and pharmacogenomic perspectives.Naunyn-Schmiedeberg's archives of pharmacology · 2026Review
- Review
- Pharmacogenetics in IBS: update and impact of GWAS studies in drug targets and metabolism.Expert opinion on drug metabolism & toxicology · 2024Review
- The Associations of Single Nucleotide Polymorphisms with Risk and Symptoms of Irritable Bowel Syndrome.Journal of personalized medicine · 2022Article
- Uncovering the pathophysiology of irritable bowel syndrome by exploring the gut-brain axis: a narrative review.Annals of translational medicine · 2021Review
- Intestinal barrier dysfunction in irritable bowel syndrome: a systematic review.Therapeutic advances in gastroenterology · 2021Review
- TNFSF15 Promotes Antimicrobial Pathways in Human Macrophages and These Are Modulated by TNFSF15 Disease-Risk Variants.Cellular and molecular gastroenterology and hepatology · 2021Article
- IBS-Symptoms in IBD Patients-Manifestation of Concomitant or Different Entities.Journal of clinical medicine · 2020Review
- Ethnic differences in genetic polymorphism associated with irritable bowel syndrome.World journal of gastroenterology · 2020Review
- Irritable Bowel Syndrome between Molecular Approach and Clinical Expertise-Searching for Gap Fillers in the Oxidative Stress Way of Thinking.Medicina (Kaunas, Lithuania) · 2020Review
- Neuroimmunogastroenterology: At the Interface of Neuroimmunology and Gastroenterology.Frontiers in neurology · 2020Review
- TL1A (TNFSF15) and DR3 (TNFRSF25): A Co-stimulatory System of Cytokines With Diverse Functions in Gut Mucosal Immunity.Frontiers in immunology · 2019Review
- Reduced monocyte and macrophage TNFSF15/TL1A expression is associated with susceptibility to inflammatory bowel disease.PLoS genetics · 2018Article
- Female-Specific Association Between Variants on Chromosome 9 and Self-Reported Diagnosis of Irritable Bowel Syndrome.Gastroenterology · 2018Article
- Irritable bowel syndrome in children: Current knowledge, challenges and opportunities.World journal of gastroenterology · 2018Review
- Article
- Death Receptor 3 regulates distinct pathological attributes of acute versus chronic murine allergic lung inflammation.Cellular immunology · 2017Article
- Pharmacogenetics and the treatment of functional gastrointestinal disorders.Pharmacogenomics · 2017Review
- The mucosal immune system: master regulator of bidirectional gut-brain communications.Nature reviews. Gastroenterology & hepatology · 2017Review
1 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors at 7 institutions in 2 countries.
Funding
Abstract
backgroundIrritable bowel syndrome (IBS) is the most common gastrointestinal disorder, affecting more than 10% of the general population worldwide. Although a genetic component is suspected, unambiguous susceptibility genes have so far not been identified. This study tested the hypothesis that genes contributing to epithelial barrier integrity, control of mucosal immune responses and interactions with bacteria in the gut are associated with IBS.
methodsSingle nucleotide polymorphisms (SNPs) corresponding to top signals of association with Crohn's disease at 30 known susceptibility loci were tested for their effect on IBS risk in 1992 individuals from two independent case-control cohorts from Sweden and the USA. Association tests included a conservative Bonferroni correction for multiple comparisons, and were also performed on specific subgroups of patients characterised by constipation (IBS-C), diarrhoea (IBS-D) or alternating constipation and diarrhoea (IBS-A).
resultsThe Crohn's disease risk allele rs4263839 G in the TNFSF15 gene was significantly associated with an increased risk of both IBS (p=2.2×10(-5); OR 1.37) and more pronouncedly, IBS-C (p=8.7×10(-7); OR 1.79) in the entire sample. Similar associations and risk effects of the same magnitude were observed in the two cohorts analysed separately. A correlation between rs4263839 genotype and TNFSF15 mRNA expression was detected both in peripheral blood and in rectal mucosal biopsies from healthy individuals (combined p=0.0033).
conclusionsTNFSF15 is a susceptibility gene for IBS and IBS constipation. As TL1A, the protein encoded by TNFSF15, contributes to the modulation of inflammatory responses, the results support a role of immune activation in IBS.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.